NCT03641352 - The Efficacy and Safety of CKD-501 Added to D150 Plus D759 Therapy in Patients With Type 2 Diabetes | Biotech Hunter

Enrollment

240

Participants

Timeline

Start Date

May 2, 2018

Primary Completion Date

April 30, 2021

Study Completion Date

November 30, 2022

Conditions

Type2 Diabetes

Interventions

DRUG

CKD-501 0.5mg

CKD-501 0.5mg, orally, 1 tablet once a dqy for 24weeks or 52weeks (if extension study) with D150 and D759

DRUG

Placebo

Placebo, orally, 1 tablet once a dqy for 24weeks or 52weeks (if extension study) with D150 and D759. CKD-501 placebo will be changed to CKD-501 from extension study to EOS(end of study).

Trial Locations (1)

Unknown

RECRUITING

The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul